Exhibit 12.1

Baxter International Inc. and Subsidiaries

Computation of Ratio of Earnings to Fixed Charges

(unaudited — in millions, except ratios)

	Six  Months Ended June  30, 2012			Years Ended December 31,
				2011			2010			2009			2008			2007
Income before income taxes	$	1,549		$	2,809		$	1,890		$	2,734		$	2,462		$	2,128
Fixed charges
Interest costs (1)		77			132			148			145			165			136
Estimated interest in rentals (2)		34			68			61			57			54			52
Fixed charges as defined		111			200			209			202			219			188
Adjustments to income
Interest costs capitalized		(22	)		(40	)		(33	)		(28	)		(17	)		(12	)
Net losses (gains) of less than majority-owned affiliates, net of dividends		1			4			(1	)		—			1			—
Income as adjusted	$	1,639		$	2,973		$	2,065		$	2,908		$	2,665		$	2,304
Ratio of earnings to fixed charges (3)		14.77			14.87			9.88			14.40			12.17			12.26

(1) Excludes interest on uncertain tax positions.

(2) Represents the estimated interest portion of rents.

(3) Excluding the following pre-tax special items included in “Income before income taxes,” the ratio of earnings to fixed charges was 14.44, 16.74, 15.05, 15.19, 12.97 and 13.25 in 2012, 2011, 2010, 2009, 2008 and 2007, respectively.

2012: $91 million of gains related to the reduction of certain contingent payment liabilities associated with prior acquisitions, $78 million of business development charges and $23 million of net benefit from reserve adjustments, which primarily related to an adjustment to the COLLEAGUE infusion pump reserves.

2011: $192 million business optimization charge, $103 million of charges principally related to asset impairments and a contribution to the Baxter International Foundation and a $79 million charge relating to the resolution of litigation pertaining to average wholesale prices and certain historical rebate and discount adjustments.

2010: $588 million charge relating to infusion pumps, $257 million business optimization charge, $112 million impairment charge, $62 million litigation-related charge, $34 million of charges relating to acquired in-process research and development (IPR&D) and a $28 million charge to write down accounts receivable in Greece.

2009: $79 million business optimization charge, $27 million charge relating to infusion pumps and a $54 million impairment charge.

2008: $125 million charge relating to infusion pumps, $31 million impairment charge and $19 million of charges relating to acquired IPR&D.

2007: $70 million charge for restructuring, $56 million charge relating to litigation and $61 million of charges relating to acquired IPR&D.